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ABSTRACT 
Niosomes have potential applications in topical drug delivery system. Niosomes play an increasingly important role in drug de livery as they can 
reduce toxicity and modify pharmacokinetic and bio-availability. Topically applied niosomes can increase the residence time of drugs in the 
stratum corneum and epidermis, while reducing the systemic absorption of the drug. It can act as drug containing reservoirs and the 
modification of the vesicular compositions or surface properties can adjust the drug release rate and the affinity for the target site. Itraconazole 
is a triazole derivative useful in the treatment of number of fungal infections. This includes aspergillosis, blastomycosis, coccidioidomycosis, 
histoplasmosis, and paracoccidioidomycosis. It may be given by mouth or intravenously. Itraconazole niosomes were prepared by thin film 
hydration method using span 20, 40, 60 (as non-ionic surfactant) and cholesterol (as stable vesicle forming agent). Niosomes were prepared 
using different ratio of drug: surfactant: cholesterol (1:1:1, 1:2:1, 1:3:1). The niosomal dispersion was evaluated for vesicle size, surface 
morphology, percent entrapment efficiency, drug content and in vitro drug release. The entrapment efficiency and drug content were calculated 
at 262 nm using UV spectrophotometer. The entrapment efficiency was found to be 57.2%, 73.2% and 61.2% for the formulations ITZ 20-3, ITZ 
40-2 and ITZ 60-1. Itraconazole niosomal gel was prepared using Carbopol 940, glycerol, Triethanolamine and distilled water. Evaluation of 
niosomal gel was determined by physical appearance, pH, viscosity, drug content, entrapment efficiency and In-vitro permeation studies. The 
percentage of the drug release from the niosomal gel was found to be 55.67 % for ITZG-2. The present study demonstrates prolongation of drug 
release, an increase in amount of drug retention into skin and improved permeation across the skin after encapsulation of Itraconazole into 
niosomal topical gel. 
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Drug delivery systems using vesicular carriers such as 
liposomes1 and niosomes2 have distinct advantages over 
conventional dosage forms because the vesicle can act as 
drug containing reservoirs. Most antifungal drug substances 
are lipophilic compounds, which are practically insoluble in 
water3. For skin care and the topical treatment of 
dermatological disease, a wide choice of vehicles ranging 
from solids to semisolids and liquid preparations is available 
to clinicians and patients4. Topical application of 
antimicrobial agents is a useful tool for the therapy of skin 
and soft-tissue infections4. A number of strategies to deliver 
antifungal using nanocarriers are developed to facilitate drug 
targeting infected cells. Nanosized carriers have been 
receiving special attention with the aim of minimizing the 
side effects and improving efficacy of drug therapy. Several 
nanosized delivery systems have already proved their 
effectiveness in antifungal therapy5. The total therapeutic 
effect of percutaneous preparations depends not only on the 
action of the drug itself, but also on other factors related to 
the structure of the vehicle. Taking into account the 
peculiarities of fungal parasites, the focus is placed 
particularly on lipid-based vehicles and earlier studies have 
shown that results in improved antifungal activity6. Many 
techniques have been aimed to disrupt and weaken the 
highly organized intercellular lipids in an attempt to enhance 
drug transport across the intact skin; one of them is the 
vesicle formulation as skin delivery system7-10. Niosomes 
have been recognized as good vehicles for the topical 
delivery of drugs11. They serve as organic solvent for the 
solubilization of poorly soluble drugs, for instances 
corticosteroids; as a result, higher local drug concentrations 
at the maximum thermodynamic activity can be applied. 
They may serve as a local depot for the sustained release of 
dermal active compounds including antibiotics, 
corticosteroids or retinoic acid. By virtue of penetration of 
individual phospholipid molecules or nonionic ether 
surfactants into the lipid layers of the stratum corneum and 
epidermis, they may serve as penetration enhancer and 
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facilitate dermal delivery leading to higher localized drug 
concentrations. They may serve as rate-limiting membrane 
barrier for the modulation of systemic absorption, that is, 
they may serve as controlled transdermal delivery systems. 
Mainly two types of vesicle skin interactions occurs during in 
vitro studies using human skin which may induce various 
effects on dermal or transdermal drug delivery12-14 First, the 
vesicles in contact with stratum corneum aggregate fuse and 
adhere to the cell surface. It is believed that this interaction 
leads to a high thermodynamic activity gradient of the drug 
at the vesicle stratum corneum interface, which is the driving 
force for penetration of the lipophilic drugs across the 
stratum corneum. Secondly, this type of interaction involves 
the ultrastructural changes of the intercellular lipid regions 
of the stratum corneum and its deeper layers at maximum 
depth of about 10 μm as revealed by freeze fracture electron 
microscopy (FFEM) and Small Angle X-ray Scattering (SAXS). 
Itraconazole (ITZ) is an orally active triazole antimycotic 
agent, which is active against a broad spectrum of fungal 
species including Cryptococcus, Candida, Aspergillus, 
Blastomyces and Histoplasma capsulatum var. Capsulatum15. 
ITZ has been classified as a biopharmaceutics classification 
scheme (BCS) Class II drug. It is also very lipophilic with an 
octanol/water log partition coefficient of 5.66 at a pH of 
8.116-18. It is practically insoluble in water (~4 ng/ml) 19. 
Therefore, the bioavailability of unformulated ITZ is 
extremely low. Itraconazole is a drug of choice for patients 
with indolent, nonmeningeal infections due to B. 
dermatitidis, H. capsulatum, P. brasiliensis, and C. immitis. 
Approximately half of thepatients with distal subungual 
onychomycosis respond well to Itraconazole. Itraconazole is 
often the best choice for the treatment of 
pseudallescheriasis, an infection not responding to the 
amphotericin B therapy, as well as cutaneous or 
extracutaneous sporotrichosis, tinea corporis, and extensive 
tinea versicolor. Itraconazole is used in the treatment of 
toenail onychomycosis with terbinafine as one week per 
month for three months. Itraconazole has low solubility and 
low permeation. By incorporation of Itraconazole in small 
niosomes, the drug can be targeted directly to the site of 
action, thus enhancing its therapeutic efficacy. 
MATERIALS AND METHODS  
Materials 
ITZ was kindly donated by Mylan Laboratories Limited, 
Hyderabad, India.  Cholesterol, Span 20, Span 40 and Span 60 
were obtained from Central drug house Pvt. Ltd., New Delhi. 
Carbopol 940 was obtained from Qualikems Fine Chem. Pvt. 
Ltd., Barodra. Chloroform was obtained from Thermo Fischer 
Scientific India Pvt. Ltd., Mumbai. Methanol was obtained 
from Merck Specialities Ltd. 
Formulation of Itraconazole niosomes 
The niosomal formulations were prepared by thin film 
hydration technique. Accurately weighed quantities of drug 
(100mg), non-ionic surfactant (Span 20, 40, 60) and 
cholesterol were dissolved in sufficient quantity of solvent 
mixture (Chloroform: Methanol 2:1) to give a clear solution. 
The resulting solution is poured into a 1000 ml rotary flask 
and evaporated under vacuum (20-25mm Hg) at 60°±2°C 
with the rotation speed of 100 rpm to form a uniform thin 
dry film. The rotary flask was removed from the bath and 
allowed to return to room temperature. The thin film formed 
was hydrated with 20 ml of distilled water while rotating the 
flask at 50 rpm (gentle agitation) at a temperature 60°±2°C. 
The resulting niosomal suspension was stored in a tightly 
closed container in a refrigerator20. 
 








ITZ20-1 Span 20 1:1:1 
ITZ20-2 Span 20 1:2:1 
ITZ20-3 Span 20 1:3:1 
ITZ40-1 Span 40 1:1:1 
ITZ40-2 Span 40 1:2:1 
ITZ40-3 Span 40 1:3:1 
ITZ60-1 Span 60 1:1:1 
ITZ60-2 Span 60 1:2:1 
ITZ60-3 Span 60 1:3:1 
 
Optimization of process-related variables 
Effect of hydration time 
The niosomal formulations containing Span 40 at different 
ratios and a fixed amount of cholesterol (1:1:1, 1:2:1) were 
hydrated with 10 ml of distilled water for 30 minutes, 60 
minutes and 90 minutes. The vesicle formation and 
entrapment efficiency of the formulations were calculated by 
centrifugation method. 
Effect of capacity and rotational speed of evaporator 
flask 
The thickness and uniformity of the film depends upon the 
rotational speed of the evaporator flask. The niosomal 
formulations were subjected to various speeds i.e. 50 rpm, 
100 rpm and 150 rpm. The appearance of the film was 
checked by visual observation. 
Effect of sonication time 
The Niosomal formulations containing Span 40 at different 
ratios and a fixed amount of Cholesterol (1:1, 2:1, 3:1) were 
subjected to ultrasonic vibration using Ultrasonicator. To 
study the effect of sonication time, the formulations were 
subjected to sonication for various time intervals (1 min, 2 
min, 3 min, 4 min and 5 min). The entrapment efficiency of 
the formulations was measured21, 22. 
Formulation of niosome entrapped itraconazole gel 
The promising niosomal suspension, (formulation of 
niosomes prepared using the optimized ratio of surfactants) 
containing Itraconazole equivalent to 2% w/w was 
incorporated into the gel base composed of Carbopol 940 
(0.5, 1 and 1.5 %%), Glycerol (10%), Triethanolamine (q.s.) 
and distilled water up to 15gm20. 
Characterization of niosomes 
Particle size analysis 
The Niosomal suspension was diluted, filled in a cuvette 
using suitable blank and the average vesicle size of the 
Niosomes was determined using Malvern zeta sizer23. 
Drug content analysis 
The amount of drug in the formulation was determined by 
lysing the niosomes using 50% n-propanol. 1 ml of the 
niosomal preparation was pipetted out, sufficient quantity of 
50% n-propanol was added and shaken well for the complete 
lysis of the vesicles. After suitable dilution with the 
phosphate buffered saline of pH 7.4 containing 10% 
Methanol, the absorbance of the solution was measured at 
262 nm in the UV- Visible Spectrophotometer. The excipients 
mixture without the drug treated in the similar manner as 
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the niosomal suspension was used as blank. The drug 
content was calculated24. 
Estimation of entrapment efficiency 
The entrapment efficiency of the formulations was 
determined by centrifuging 1 ml of the suspension diluted to 
10 ml with distilled water at 15,000 rpm for 60 minutes at 
4°C using a high speed cooling centrifuge in order to separate 
niosomes from unentrapped drug. The free drug 
concentration in the supernatant was determined at 262nm 
using UV-Visible Spectrophotometer after suitable dilution. 
The percentage of drug entrapment in niosomes was 
calculated using the following formula21, 
% drug entrapment = (Total drug- Drug in supernatant liquid) 
X 100 Total drug 
In- Vitro release study 
In- vitro drug release pattern was studied using dialysis 
membrane. The niosomal preparation after separation of 
unentrapped drug was placed in an open ended glass tube, 
one end of which was tied with the dialysis membrane. This 
acted as the donor compartment. Then the open ended tube 
was placed in a beaker containing 100 ml phosphate 
buffered saline pH 7.4, which acted as receptor 
compartment. The temperature of the receptor medium was 
maintained at 37°±2°C and the medium was agitated at a 
speed of 100 rpm using a magnetic stirrer. 5ml of the 
samples were collected at a predetermined time and 
replenished immediately with the same volume of fresh 
buffer PBS pH 7.4. The sink condition was maintained 
throughout the experiment. The collected samples were 
analyzed spectrophotometrically at 262nm using UV-Visible 
spectrophotometer25. 
Scanning electron microscopy 
The sizes of the vesicles were measured by scanning electron 
microscope (HITACHI S- 150). A small amount of sample of 
niosomes suspension was taken in cover slip on the 
specimen stub. It was coated with carbon and then with gold 
vapour using Hitachi vacuum evaporator, model HITACHI S 5 
GB. The samples were examined under scanning electron 
microscope, which is operated at 15 kilovolts and then 
photographed26. 
Zeta potential analysis 
Zeta potential analysis was used to measure the stability of 
niosome by studying its colloidal property. Aggregation is 
attributed to the shielding of the vesicle surface charge by 
ions in solution and thereby reducing the electrostatic 
repulsion. Vesicle surface charge can be estimated by 
measurement of particle electrophoretic mobility and is 
expressed as the Zeta potential. The study was conducted 
using Malvern Zeta Analyzer27. 
Characterization of niosomes containing gel 
Physical appearance 
The prepared gel was examined for clarity, color, 
homogeneity and the presence of foreign particles. 
pH 
2.5gm of gel was accurately weighed and dispersed in 25 ml 
of distilled water. The pH of the dispersion was measured by 
using a digital pH meter. 
Viscosity measurement 
Viscosity was determined by Brookfield programmable DV 
III ultra viscometer. In the present study, spindle no. CP 52 
with an optimum speed of 0.01 rpm was used to measure the 
viscosity of the preparation. 
Content uniformity  
The drug content of the prepared gel was carried out by 
dissolving accurately weighed quantity of gel equivalent to 
10mg of the drug in 100 ml volumetric flask and suitable 
volume of 50% n-propanol for lysis of the vesicles. The 
volume was made up to 100 ml with methanol. The content 
was filtered through Whatman filter paper No.41. 5 ml of 
above solution was taken into a 50ml volumetric flask and 
volume was made upto mark with methanol. The content of 
Itraconazole was determined at 262 nm against blank by 
using the Shimadzu UV/visible spectrophotometer20. 
Spreadability  
An important criterion for gels is that it must possess good 
spreadability. Spreadability is a term expressed to denote the 
extent of area to which the gel readily spreads on application 
to skin. The therapeutic efficacy of a formulation also 
depends on its spreading value. A special apparatus has been 
designed to study the spreadability of the formulations. 
Spreadability is expressed in terms of time in seconds taken 
by two slides to slip off from formulation, placed between, 
under the application of a certain load. Lesser the time taken 
for the separation of two slides, better the spreadability.  It is 
determine by formula given below. 
 
   Where, S=Spreadability (gcm/sec) 
    m = weight tied to the upper slide (20 grams)   
    l= length of glass slide (6cms).  
   t = time taken is seconds. 
Estimation of entrapment efficiency 
The entrapment efficiency of the formulations was 
determined by centrifuging 0.5 g of the gel equivalent to 
10mg of Itraconazole diluted to 10 ml with distilled water at 
15,000 rpm for 60 minutes at 4°C using a high speed cooling 
centrifuge in order to separate niosomes from unentrapped 
drug. The free drug concentration in the supernatant was 
determined at 262 nm using UV-Visible Spectrophotometer 
after suitable dilution. The percentage of drug entrapment in 
niosomes was calculated using the following formula26, 
%drug entrapment= (Total drug- Drug in supernatant 
liquid)/ Total drug X 100 
In-vitro drug diffusion study 
In- vitro drug diffusion study was studied using dialysis 
membrane. The niosomal gel equivalent to 10mg of the drug 
was placed in an open ended glass tube, one end of which 
was tied with the dialysis membrane. This acted as the donor 
compartment. Then the open ended tube was placed in a 
beaker containing 100 ml phosphate buffered saline pH 7.4, 
which acted as receptor compartment. The temperature of 
the receptor medium was maintained at 37°±2°C and the 
medium was agitated at a speed of 100 rpm using a magnetic 
stirrer. 5ml of the samples were collected at a predetermined 
time and replenished immediately with the same volume of 
fresh buffer PBS pH 7.4. The sink condition was maintained 
throughout the experiment. The collected samples were 
analyzed spectrophotometrically at 262nm using UV- Visible 
spectrophotometer25. 
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Stability studies 
The stability studies of the optimized niosomal formulations 
were performed at different conditions of temperature and 
the effect on physical characterisitics, entrapment efficiency 
and drug content was noted. The niosomal dispersions were 
kept in the air tight containers and stored at 2-8°C and at 
room temperature (30±2°C) for 30 days and 2 ml samples 
were withdrawn every 15 days and at the end of 45 days. 
The samples were analyzed spectrophotometrically at λmax 
262nm after disrupting the vesicles with 50% n-propanol28. 
RESULTS AND DISCUSSION 
The IR spectrum of sample drug shows the peak values 
which are characteristics of the drug and the graph were 
shown in Fig. 1. The λmax of itraconazole was determined by 
running the spectrum of drug solution in double beam 
ultraviolet spectrophotometer (Shimadzu-1601, Kroyoto, 
Japan) using7.4 pH buffer solution as solvent and 
concentration range of 2-10μg/ml Fig. 2. 
 
 
Figure 1 FT- IR spectra of Itraconazole 
 
 
Figure 2 The linear regression analysis for standard 
curve 
In the present research work Itraconazole niosomes were 
prepared using different ratios of drug: surfactant: 
cholesterol and optimization of process-related variables by 
the thin film hydration method. The prepared Itraconazole 
niosomes were evaluated for various parameters like 
particle size, shape, entrapment efficiency and in vitro drug 
release. Finally, the promising formulation was selected and 
then it was incorporated into the gel for topical uses. The 
result of average vesicle size, % entrapment efficiency and 
zeta potential of optimized formulation (ITZ40-2) of 
niosomes was given in table 2. 
 
Table 2 Characterization of Optimized formulation of Niosomes 
Characterization 
. 






ITZ40-2 272.3 73.03±2.39 -47.2±0.2 
 
The result of viscosity (cps), % drug content, % Entrapment efficiency, spreadability (g.cm/sec) and pH of optimized 
formulation (ITZG-2) of niosomes gel was given in table 3. 












ITZG-2 2345±2.07 95.56±0.12 68.2 14.22±0.25 7.1±0.15 
ITZG * Optimized gel formulation (n=3) 
 
y = 0.0516x - 0.0078 
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The in-vitro diffusion study is carried by using Franz 
Diffusion Cell. Egg membrane is taken as semi permeable 
membrane for diffusion. The result of In vitro drug release 
study of prepared gel formulation was given in table 4. In 
vitro drug release of plain gel was found to be 78.59 in 6 hrs 
but niosomal gel gave drug release 98.87 in 24hrs. Gel 
formulation containing niosomes loaded with Itraconazole 
showed prolonged action than formulations containing 
Itraconazole in non-niosomal form. 
Stability studies of the Itraconazole optimized gel 
formulations (ITZG-2) were carried out by storing at 4°C-8°C 
(refrigeration temperature) and 25°C ±2°C (room 
temperature) for a period of 45 days as per ICH 
(International Conference on Harmonization) guidelines and 
result was given in table 5. 
The entrapment efficiency of the drug in the niosomal gel 
was estimated immediately after the preparation and after 
every 15 days for 45 days. The drug leakage from the 
vesicles was least at 4°C. This may be attributed to phase 
transition of surfactant and lipid causing leakage of vesicles 
occurs at higher temperature at storage. Hence, the 
niosomes can be stored at 4-8°C. The improved stability of 
niosomes after incorporation into the gel base may be due to 
prevention of fusion of niosomes. The higher drug skin 
retention in case of niosomal gel maybe due to creation of 
reservoir effect of drug in the skin and thereby increasing 
the drug retention capacity into the skin. 
Table 4 In vitro drug release study of prepared gel 
formulation (ITZG-2) 
Time (hr) 
% Cumulative Drug Release 
Plain gel Niosomal Gel 
0 0 0 
1 5.96 2.47 
2 28.78 28.45 
3 46.76 44.65 
4 48.81 50.45 
5 61.85 64.56 
6 78.59 69.65 
7  70.43 
8  77.45 
9  79.54 
10  81.45 
11  82.44 
12  86.67 
24  98.87 
 
Table 5 Stability study of Itraconazole niosomal gel formulation ITZG-2 at different temperature 
Time of storage 
in days 
Temperature of storage 




(%)Entrapment efficiency  
4-80C 
(refrigeration temp) 
(%) Drug Content 
25°C ±2°C 




( room tem) 
0 97.10 64.8 97.10 64.8 
15 96.90 64.5 96.10 64.0 
30 96.71 64.2 95.16 63.0 




The purpose of this research was to prepare Itraconazole 
loaded niosomes for controlled release of drug and 
incorporate it in to topical gel delivery system to reduce the 
side effects. Thin film hydration technique was employed to 
produce niosomes using non-ionic surfactants and 
cholesterol. The results of the FT- IR studies proved that 
there is no interaction between the drug cholesterol and the 
non-ionic surfactants. The process related parameters were 
optimized such as hydration time (60 minutes), sonication 
time (10minutes), rotational speed of the evaporator flask 
(initially 100 rpm, later 150 rpm). Cholesterol is used as a 
membrane additive, acts as a stabilizer as well as fluidity 
buffer to improve the stability of the vesicles. The 
formulations were prepared using different non- ionic 
surfactants by varying the surfactant concentration (Span 20, 
40 and Span 60) and keeping the cholesterol concentration 
fixed. The prolonged release of the drug from the niosome 
suggests that the frequency of administration and adverse 
effects significantly thereby improving the patient 
compliance. The administration of drug as gel type 
formulation enhances its penetration and release. 
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